Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.45 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22487911 | 0.78 | — | — | |
| SCHEMBL13327029 | 0.71 | DAO (0.41) | PDE3BPDE3ADAOPARP1TSHR | |
| SCHEMBL11929997 | 0.69 | POLB (0.39) | PDE3BPDE3ADAOGSK3BPOLB | |
| SCHEMBL17761925 | 0.68 | GPR84 (0.50) | PDE3BPDE3ADAOPARP1TSHR | |
| SCHEMBL29903956 | 0.68 | AOC3 (0.47) | DAOPOLBMEN1KMT2A | |
| SCHEMBL9963333 | 0.67 | — | — | |
| SCHEMBL12927964 | 0.67 | DAO (0.49) | DAOPOLBGPR84MEN1KMT2A | |
| SCHEMBL30315297 | 0.66 | — | — | |
| SCHEMBL10325788 | 0.66 | — | — | |
| SCHEMBL24881442 | 0.65 | PABPC1 (0.47) | DAOPARP1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226055-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-11590132-B2 | Pyruvate kinase activators for use in treating blood disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20200207785-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | PHARMARESOURCES (SHANGHAI) CO., LTD. (CN) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226055-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | PDK1, PDK2, PDK3 | PDE3B 1228/4885PDE3A 1553/4885DAO 2111/4885 |
| US-11590132-B2 | Pyruvate kinase activators for use in treating blood disorders | PDK1, PDK2, PDK3 | PDE3B 1228/4885PDE3A 1553/4885DAO 2111/4885 |
| US-20200207785-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | PDK1, PDK2, PDK3 | PDE3B 1255/4885PDE3A 1585/4885DAO 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.